Osimertinib is a third-generation irreversible EGFR-TKI that inhibits both EGFR-sensitizing and EGFR T790M mutations, and was initially approved for NSCLC with EGFR T790M mutation [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.